In this Issue:
OS in the COMFORT trials
Long-term outcomes of first-line nilotinib in CML
Long-term safety of romiplostim in chronic ITP
Silent VTE in lenalidomide-treated MM
18FDG-PET/CT parameters for primary mediastinal large B-cell lymphoma prognosis
Melphalan/prednisone with thalidomide or lenalidomide in untreated MM
Melanoma and NMSCs in HCL
Bimodal infection peaks in MM
BCR-ABL1 mutations during first-line dasatinib or imatinib for chronic-phase CML
Please login below to download this issue (PDF)